Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERCH
NCT04231877Phase 2Active, not recruiting
- Sponsor
- University of Washington
- Start
- Oct 2020
- Primary completion
- Sep 2026
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of polatuzumab vedotin, glofitamab in B-cell non-Hodgkin lymphoma, sponsored by University of Washington. Started Oct 2020; status: active, not recruiting.
02
Drugs
polatuzumab vedotinglofitamab
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT04231877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04231877.